Compare SCHL & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | IMMX |
|---|---|---|
| Founded | 1920 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.6M | 716.2M |
| IPO Year | 1995 | 2021 |
| Metric | SCHL | IMMX |
|---|---|---|
| Price | $34.91 | $12.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $40.00 | $19.20 |
| AVG Volume (30 Days) | 258.0K | ★ 1.5M |
| Earning Date | 03-19-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ 3442.86 | N/A |
| EPS | ★ 2.34 | N/A |
| Revenue | ★ $1,487,100,000.00 | N/A |
| Revenue This Year | $1.88 | N/A |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $14.96 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.69 | $1.94 |
| 52 Week High | $48.07 | $15.10 |
| Indicator | SCHL | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 28.93 | 47.68 |
| Support Level | $32.81 | $7.96 |
| Resistance Level | $36.00 | $15.10 |
| Average True Range (ATR) | 1.53 | 0.83 |
| MACD | -0.29 | -0.33 |
| Stochastic Oscillator | 11.37 | 9.40 |
Scholastic Corp is a publisher and distributor of children's books, a provider of print and digital instructional materials for grades pre-kindergarten (pre-K) to grade 12 and a producer of entertaining literary and educational children's media. The company creates quality print, digital and audio books, learning materials and programs, classroom magazines and other products that, in combination, offer children, families and educators engaging and comprehensive solutions to support children's learning and reading both at home and at school. It categorizes its businesses into four reportable segments: Children's Book Publishing and Distribution; Education; Entertainment; and International. It derives the majority of revenue from Children's Book Publishing and Distribution segment.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.